Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NxStage to raise $43 million in equity financing
The private placement consists of 9.6 million shares of NxStage common stock at a price of $4.50 per share and warrants to purchase 1.9 million shares of common
The private placement consists of 9.6 million shares of NxStage common stock at a price of $4.50 per share and warrants to purchase 1.9 million shares of common
Mary Dillahunty, vice president of intellectual property at Oncolytics, said: “This patent provides the company with additional patent protection for the use of reovirus compositions for cancers and
Biotronik’s Corox OTW BP and Corox OTW S-BP leads offer a design that allows them to fixate in even unusual coronary vessel anatomies, which can preclude the use
The DiaGenic breast cancer test offers a set of advantages over existing diagnostic methods. The use of venous blood as the test sample is both discreet and patient
Lutronic’s Spectra VRM III is said to be specifically designed to treat a wide array of dermatological and aesthetic conditions, including dermal and epidermal pigmented lesions, multicolor tattoos,
Thomas Cloud, CEO of Telemedicus, said: “Steve did a great job and definitely will be missed. We will seek his replacement and continue to progress the Dreams technology
The Osmotica product provides a controlled release tablet form of venlafaxine hydrochloride including previously unavailable 225mg dosage strength. Equal doses of venlafaxine HCl extended-release tablets are bioequivalent to
The Phase IIa MIVI-IIT trial was a sham injection controlled study in which patients were assigned to receive either 75(micro)g or 125(micro)g of microplasmin. Analysis of the full
In order to preserve the integrity of the clinical trial and allow the study to continue without introducing bias, GTx did not receive data from the interim efficacy
Extavia is the Novartis branded version of interferon beta-1b, a first-line disease-modifying therapy injected every other day for the treatment of multiple sclerosis (MS). Formerly known as NVF233,